Trial Profile
A Phase 1, Single Dose Escalation Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Feb 2020
Price :
$35
*
At a glance
- Drugs Brilacidin (Primary)
- Indications Acne; Atopic dermatitis; Hidradenitis suppurativa; Inflammatory bowel diseases; Skin and soft tissue infections; Stomatitis; Ulcerative proctitis
- Focus First in man; Pharmacokinetics
- Sponsors Innovation Pharmaceuticals
- 13 Feb 2020 Status changed from active, no longer recruiting to completed, according to an Innovation Pharmaceuticals Media Release.
- 13 Feb 2020 According to an Innovation Pharmaceuticals media release, Professor Howard Stevens is the principal investigator of this trial.
- 13 Feb 2020 According to an Innovation Pharmaceuticals media release, primary endpoint has been met in this trial.